AskBio Receives FDA Fast Track Designation for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) ...Middle East

RESEARCH TRIANGLE PARK, N.C., June 28, 2021 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for the LION-101 gene...

Hence then, the article about askbio receives fda fast track designation for lion 101 a novel investigational aav gene therapy for the treatment of limb girdle muscular dystrophy type 2i r9 lgmd2i r9 was published today ( Monday 28/06/2021 - 02:30 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AskBio Receives FDA Fast Track Designation for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) )

Also on site :

• OpenAI buys tiny health records startup Torch for, reportedly, $100M
• Meta-backed Hupo finds growth after pivot to AI sales coaching from mental wellness
• TCL Dominates CES 2026 with Ultimate Display Innovation